je.st
news
Tag: mercks
CHMP Issues Positive Opinion for Tablet Formulation of Merck's NOXAFIL
2014-03-01 00:42:42| Biotech - Topix.net
Merck , known as MSD outside the United States and Canada, announced today that the Committee for Medicinal Products for Human Use of the European Medicines Agency recipients with graft-versus-host disease or those with hematologic malignancies with prolonged neutropenia from chemotherapy.
Tags: issues
positive
opinion
formulation
CHMP Issues Positive Opinion for Tablet Formulation of Mercks NOXAFIL (posaconazole)
2014-02-28 14:30:00| Merck.com - Corporate News
Dateline City: WHITEHOUSE STATION, N.J. WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending approval of a new, investigational tablet formulation of NOXAFIL (posaconazole). Language: English Contact: MerckMedia:Pam Eisele, 267-305-3558orRobert Consalvo, 908-423-6595orInvestor:Carol Ferguson, 908-423-4465orJustin Holko, 908-423-5088 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: issues
positive
opinion
formulation
FDA Accepts for Review Mercks Biologics License Application for V503, Investigational 9-valent Human Papillomavirus Vaccine
2014-02-20 14:30:00| Merck.com - Research & Development News
Dateline City: WHITEHOUSE STATION, N.J. WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, announced today that the Biologics License Application for V503, its investigational 9-valent human papillomavirus (HPV) vaccine, has been accepted for standard review by the U.S. Food and Drug Administration. About Merck Language: English Contact: MerckMedia Contacts:Pamela Eisele, 267-305-3558Imraan Munshi, 215-652-0059orInvestor Contacts:Carol Ferguson, 908-423-4465Justin Holko, 908-423-5088 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: review
application
human
license
Exclusive: Bayer, Novartis, others eye Merck's consumer health unit - sources
2014-02-20 07:07:35| Biotech - Topix.net
A handful of consumer and healthcare companies including Bayer AG and Novartis are exploring a deal for Merck & Co Inc's consumer healthcare business, as they seek to gain scale in a fragmented industry, according to several people familiar with the matter.
Exclusive: Bayer, Novartis, others eye Merck's consumer health unit - sources
2014-02-19 23:10:55| Chemicals - Topix.net
A handful of consumer and healthcare companies including Bayer AG and Novartis are exploring a deal for Merck & Co Inc's consumer healthcare business, as they seek to gain scale in a fragmented industry, according to several people familiar with the matter.
Sites : [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] next »